These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30737018)

  • 1. [MSI Metastatic solid tumors treatment and immunotherapies].
    Bouchez C; Kempf E; Tournigand C
    Bull Cancer; 2019 Feb; 106(2):143-150. PubMed ID: 30737018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and patients treated for cancer with microsatellite instability.
    Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T
    Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiology of microsatellite instability across solid neoplasms].
    Colle R; Cohen R
    Bull Cancer; 2019 Feb; 106(2):114-118. PubMed ID: 30409467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and molecular consequences of microsatellite instability in human cancers].
    Hamelin R; Chalastanis A; Colas C; El Bchiri J; Mercier D; Schreurs AS; Simon V; Svrcek M; Zaanan A; Borie C; Buhard O; Capel E; Zouali H; Praz F; Muleris M; Fléjou JF; Duval A
    Bull Cancer; 2008 Jan; 95(1):121-32. PubMed ID: 18230578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
    Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
    Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
    Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
    Danaher P; Warren S; Ong S; Elliott N; Cesano A; Ferree S
    J Immunother Cancer; 2019 Jan; 7(1):15. PubMed ID: 30665466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.
    Kubecek O; Trojanova P; Molnarova V; Kopecky J
    Med Hypotheses; 2016 Aug; 93():74-6. PubMed ID: 27372860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.
    Li N; Wan Z; Lu D; Chen R; Ye X
    Front Immunol; 2022; 13():1088683. PubMed ID: 36703977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
    Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
    Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
    Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers].
    El-Ghazzi N; Rousseau B; Rodrigues M
    Bull Cancer; 2023 Jan; 110(1):11-13. PubMed ID: 36357200
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
    Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
    Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Ta RM; Hecht JL; Lin DI
    Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
    Chang L; Chang M; Chang HM; Chang F
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.